Health‐Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer
暂无分享,去创建一个
E. Tokunaga | M. Goetz | S. Johnston | J. Huober | Miguel Martín | M. Toi | I. Park | C. Stoffregen | V. André | M. C. Gainford | G. Price | S. Shekarriz
[1] P. Neven,et al. Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy. , 2020, The oncologist.
[2] P. Neven,et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 , 2019, JAMA oncology.
[3] H. Iwata,et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer , 2019, npj Breast Cancer.
[4] P. Fayers,et al. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States. , 2019, European journal of cancer.
[5] G. Scagliotti,et al. Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016 , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] L. Fallowfield. Quality of life assessment using patient-reported outcome (PRO) measures: still a Cinderella outcome? , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[8] N S El Saghir,et al. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] G. Sledge,et al. The association of early toxicity and outcomes for patients treated with abemaciclib. , 2018 .
[10] P. Neven,et al. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] M. Goetz,et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] P. Neven,et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] C. Hudis,et al. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer , 2017, Clinical Cancer Research.
[14] A. Tutt,et al. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] R. Hofheinz,et al. Patient preferences for palliative treatment of locally advanced or metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction: a choice-based conjoint analysis study from Germany , 2016, BMC Cancer.
[16] Tuan S. Nguyen,et al. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. , 2016, Cancer discovery.
[17] W. Gradishar,et al. NCCN Guidelines Updates: Breast Cancer. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.
[18] S. Loi,et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] R. Gralla,et al. Determining issues of importance for the evaluation of quality of life and patient-reported outcomes in breast cancer: results of a survey of 1072 patients , 2015, Breast Cancer Research and Treatment.
[20] P. Iversen,et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine , 2014, Investigational New Drugs.
[21] Kathleen A Cronin,et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. , 2014, Journal of the National Cancer Institute.
[22] P. Auquier,et al. Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization? , 2013, Quality of Life Research.
[23] Tiffany Shao,et al. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] P. Dobkin,et al. Fear of Pain in Patients With Advanced Cancer or in Patients With Chronic Noncancer Pain , 2011, The Clinical journal of pain.
[25] T. Reimer,et al. Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. , 2010, Deutsches Arzteblatt international.
[26] N. Aaronson,et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[28] W. Gradishar,et al. NCCN Guidelines Update: Breast Cancer. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.
[29] A. Tutt,et al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] D. Osoba,et al. Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.